NASDAQ: FLKS | Healthcare / Biotechnology / USA |
0.3600 | 0 | 0.00 | Vol 1 618 964 | 1Y Perf -91.52% |
Feb 15th, 2019 16:00 |
BID | 0.3500 | ASK | 0.3600 | ||
Open | 0.3600 | Previous Close | 0.3600 | ||
Pre-Market | 0.35 | After-Trading | 0.34 | ||
-0.01 -2.78% | -0.02 -5.56% |
Target Price | 1.00 | Analyst Rating | Hold 3.00 | |
Potencial % | 177.78 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12M | -/-100/-100 | Value Ranking | — - | |
Insiders Value % 3/6/12M | -/-100/-100 | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12M | -/-100/-100 | Income Ranking | — - | |
Market Cap (mil) | 7 | Earnings Rating | Neutral | |
Price Range Ratio 52wk % | 1.15 | Earnings Date | 6th Mar 2019 |
Today's Price Range 0.33000.3700 | 52wk Range 0.26008.98 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Month | 9.09% | ||
3 Months | -20.00% | ||
6 Months | -32.08% | ||
1 Year | -91.52% | ||
3 Years | -94.88% | ||
5 Years | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Quick Ratio | 4.50 | |||
Current Ratio | 4.70 | |||
Long Term Debt to Total Capital | - | |||
Total Debt to Equity | - | |||
Interest Coverage | - | |||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Gross Margin | 48.90 | |||
EBIT Margin | -2 938.30 | |||
EBITDA Margin | -2 912.10 | |||
Pre-tax Profit Margin | - | |||
Profit Margin | - |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | 0.52 | |||
PS Ratios | 8.56 | |||
Price to Cash Flow | - | |||
Price to Free Cash Flow | -0.30 | |||
Cash Flow Per Share | -1.46 | |||
Price to Tangible Book | 0.52 | |||
Book Value per Share | 0.61 | |||
Enterprise Value (in ths.) | -7 269 |
Management Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Return on Equity (5Y Avg) | - | |||
ROE last 12 Months | -118.32 | |||
Return on Assets (5Y Avg) | - | |||
ROA last 12 Months | -101.34 | |||
Return on Capital (5Y Avg) | - | |||
ROC last 12 Months | -118.32 | |||
Return on invested Capital Q | -21.57 | |||
Return on invested Capital Y | -77.88 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 11.10 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Revenue LTM (in ths.) | 665 | |||
Revenue per Share | 0.04 | |||
Revenue Growth 3 Years | - | |||
Revenue Growth 5 Years | - |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2018 | - | -0.15 | - |
Q02 2018 | -0.39 | -0.50 | -28.21 |
Q01 2018 | -0.50 | -0.46 | 8.00 |
Q04 2017 | -0.56 | -0.46 | 17.86 |
Q03 2017 | -0.62 | -0.54 | 12.90 |
Q02 2017 | -0.63 | -0.51 | 19.05 |
Q01 2017 | -0.63 | -0.49 | 22.22 |
Q04 2016 | -0.84 | -0.48 | 42.86 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2018 QR | -0.25 | 26.47 | Positive |
12/2018 QR | -0.13 | 61.76 | Positive |
12/2018 FY | -1.23 | 0.00 | - |
12/2019 FY | -0.55 | 0.00 | - |
Next Report Date | 6th Mar 2019 |
Estimated EPS Next Report | - |
Estimates Count | - |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1 618 964 |
Shares Outstanding (in ths.) | 18 069 |
Trades Count | 967 |
Dollar Volume | 530 929 |
Avg. Volume | 1 855 823 |
Avg. Weekly Volume | 785 451 |
Avg. Monthly Volume | 570 713 |
Avg. Quarterly Volume | 1 240 537 |
Week | Month | Three Months | Six Months |
---|---|---|---|
Bearish Bullish 100%0% | Bearish Bullish 65%35% | Bearish Bullish 38%62% | Bearish Bullish 64%36% |
There are no comments yet.
![]() | ![]() | ![]() | ![]() | ![]() | ![]() |